Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy

Frontiers in Immunology

Zhenqiang Sun¹  Yanxin Xu¹  Shengyun Hu¹  Yaxin Guo²  Chen Chen³ 

[1] Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China;School of Life Sciences, Zhengzhou University, Zhengzhou, China;

关键词: CRISPR/Cas9;    PD-1;    PD-L1;    tumor immunity;    immunotherapy;   

DOI  :  10.3389/fimmu.2022.848327

来源: DOAJ

【 摘 要 】

Clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease9 (CRISPR/Cas9) gene editing technology implements precise programming of the human genome through RNA guidance. At present, it has been widely used in the construction of animal tumor models, the study of drug resistance regulation mechanisms, epigenetic control and innovation in cancer treatment. Tumor immunotherapy restores the normal antitumor immune response by restarting and maintaining the tumor-immune cycle. CRISPR/Cas9 technology has occupied a central position in further optimizing anti-programmed cell death 1(PD-1) tumor immunotherapy. In this review, we summarize the recent progress in exploring the regulatory mechanism of tumor immune PD-1 and programmed death ligand 1(PD-L1) based on CRISPR/Cas9 technology and its clinical application in different cancer types. In addition, CRISPR genome-wide screening identifies new drug targets and biomarkers to identify potentially sensitive populations for anti-PD-1/PD-L1 therapy and maximize antitumor effects. Finally, the strong potential and challenges of CRISPR/Cas9 for future clinical applications are discussed.

【 授权许可】

Unknown